Discontinued — last reported Q4 '22
Business Segments · Total Assets
Pharmaceutical — Total Assets
Johnson & Johnson Pharmaceutical — Total Assets decreased by 9.2% to $58.44B in Q4 2022 compared to the prior quarter.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2009
Last reportedQ4 2022
Rolls up toTotal Assets
How to read this metric
An increase suggests capital expansion or investment in the segment, while a decrease may indicate divestitures or asset depreciation.
Detailed definition
This represents the total book value of assets specifically allocated to or utilized by the pharmaceutical operating seg...
Peer comparison
Standard segment-level asset reporting found in most diversified healthcare and pharmaceutical companies.
Metric ID:
jnj_segment_pharmaceutical_assetsHistorical Data
2 periods
| Q4 '21 | Q4 '22 | |
|---|---|---|
| Value | $64.38B | $58.44B |
| QoQ Change | — | -9.2% |
| YoY Change | — | -9.2% |
Range$58.44B – $64.38B
Avg YoY Growth-9.2%
Median YoY Growth-9.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's pharmaceutical — total assets?
- Johnson & Johnson (JNJ) reported pharmaceutical — total assets of $58.44B in Q4 2022.
- What does pharmaceutical — total assets mean?
- The total value of assets dedicated to the pharmaceutical business segment.